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ohe case for screening asymptomatic adults for coronary
rtery disease seems to be, on the surface, obvious. Coronary
isease is common and serious and involves a prolonged
symptomatic phase. Frequently the first clinical presenta-
ion causes serious morbidity or even death. Because of
emarkable developments in imaging technology, physicians
ow have available to them potentially powerful screening
ools that are able to identify high-risk patients. Advocates
f routine screening argue that, given the public health
onsequences of coronary disease and given the ability of
maging screening tests to stratify risk more accurately than
lassical risk factors, we are ready to issue large-scale public
ealth recommendations advocating routine screening for
any adults. Critics argue that we are not ready because we
ave no evidence that screening does what it is supposed to
o, namely, prevent premature clinical disease and deaths.
n medicine, we have seen a number of screening tests that,
hen put to the test themselves, failed to improve outcome.
ne major reason, which is nearly always overlooked in
ebates about chronic disease screening, is the phenomenon
f overdiagnosis. Screening tests are often unable to distin-
uish real disease from pseudodisease. This inherent failing
auses real harm and cannot be dismissed as an academic
ssue. It is also a major reason why we should not advocate
outine screening without first obtaining proper randomized
rial evidence of benefit.
Once upon a time, there was a diagnostic screening test
hat was so powerful it could easily identify people at risk for
serious life-threatening disease. Medical researchers ob-
erved that as the value of the test measurement increased
rom 0 to high normal, to slightly abnormal, and to grossly
bnormal, there emerged a strong gradient for the risk of
ying of the disease (1). The good news spread. Before too
ong, over 75% of potentially eligible adults had the test
erformed as part of their routine clinical care. Professional
ocieties and many prominent physicians strongly advocated
or the test (2). Decades later, because of the widespread
rom the Division of Cardiovascular Sciences, National Heart, Lung, and Bloodw
nstitute, Bethesda, Maryland.
Manuscript received January 4, 2010; accepted January 11, 2010.doption of this powerful screening test, the disease was
topped in its tracks, so much so that very few people were
ow diagnosed with advanced disease, and death from the
isease was distinctly uncommon.
Unfortunately, that is not how the story ended. The test
as a prostate-specific antigen, a marker for prostate cancer,
disease that kills 29,000 men every year in the U.S. (3).
he ability of prostate-specific antigen levels to predict the
isk of disease-related death is incontrovertible. However,
espite decades of use, we have seen no change in the rate
f diagnosis of advanced prostate cancer and no change in
he rate of prostate cancer deaths (4). There has been a
arked increase in the incidence of diagnosed prostate
ancer, as would be expected when a screening test is in
idespread use. Yet, somehow, the test seems to have failed
n its primary mission, which is to stop the disease before it
as an opportunity to cause major morbidity or mortality.
The bad news does not end there. Under the leadership of
he National Cancer Institute, a large-scale randomized trial
as designed and implemented to determine whether pros-
ate cancer screening reduces the risk of cancer-related
eath (2). The results almost exactly parallel the epidemio-
ogical data. Men who were randomized to prostate cancer
creening had a higher incidence of prostate cancer, exactly
s would be expected with use of a sensitive screening test.
owever, there was no reduction in the rate of death from
rostate cancer.
How could this be? How is it possible that a test that is
o good at predicting risk and identifying early disease could
ail to prevent morbidity and mortality? Could this be a
nique phenomenon of this particular test and this partic-
lar disease? Doubtful, as this same pattern has been
bserved for other screening tests and diseases. Screening
ests do not prevent deaths caused by neuroblastoma (5) or
elanoma (6), nor do they decrease risk of cardiovascular
vents in patients with diabetes (7). The problem is over-
iagnosis (4,8). Diagnostic tests may be extremely good at
etecting early stage disease, yet fail to determine which
ases of disease, if left alone, will eventually kill. Many,
ften most, people with abnormal screening test findings
ill nonetheless remain free of clinical disease; for example,
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July 6, 2010:106–8 Screening for Subclinical Atherosclerosismong adults with high coronary calcium scores in the
ESA (Multi-Ethnic Study of Atherosclerosis), 95% re-
ained asymptomatic over the next 5 years (9). Overdiag-
osis is not a trivial, theoretical problem for academic
urists; it leads to real harm, because patients with non-
hreatening disease are nonetheless subjected by their wor-
ied doctors to potentially risky tests, treatments, and
rocedures (10).
Our experiences with failed screening tests remind us why
number of leading prevention authorities, including the
.S. Preventive Services Task Force (11) and some cardio-
ascular thought leaders (12), insist that cardiovascular
creening tests, like all screening tests, be shown to do what
hey are supposed to do—prevent clinical disease. The
bility to predict or reclassify risk is beside the point.
There are 2 valid ways to demonstrate the clinical value of
screening test (13). The most straightforward is to
andomize subjects to receive the test or not and then follow
hem for long-term outcomes. Researchers successfully used
his approach to demonstrate the value of mammography
14) and ultrasound imaging of the abdominal aorta (15).
his is also the approach that is currently being used by the
ational Lung Screening Trial investigators (16), who
uccessfully randomized over 50,000 smokers to screening
ith either chest X-ray or computed tomography scan.
nfortunately, randomized trials that focus specifically on
iagnostic screening tests require large sample sizes and
ong follow-up periods. An alternative approach is to use a
creening test to identify subjects believed to be at high risk,
nd then randomize them to treatment or control (13). This
s the approach that was used by the JUPITER (Justification
or the Use of Statins in Prevention: An Intervention Trial
valuating Rosuvastatin) investigators to demonstrate a
ossible screening value for high-sensitivity C-reactive pro-
ein as a means of identifying people likely to benefit from
tatin therapy (17).
In his thoughtful essay, Shah (18) argues that we should
creen selected asymptomatic subjects for subclinical ath-
rosclerosis. He bases his argument on the ability of certain
creening tests, such as coronary calcium measurement, to
rovide incremental risk information over the Framingham
isk Score and evidence that screening “may improve
dherence to compliance with risk modifying interventions.”
e admits that there is no evidence showing that coronary
rtery disease screening improves clinical outcomes, and he
ncourages future trials. He laments a “double standard” by
hich the Framingham Risk Score has been accepted for
outine use, despite the absence of randomized trial evi-
ence that use of the risk score improves outcomes.
The ongoing debate about coronary artery disease screen-
ng reflects a number of other debates in medical history
bout the value of interventions that made a lot of sense, yet
ere untested. There are passionate believers who sincerely
eel that the logic is so strong (“the science is so good”) that
here should be no need for a large-scale randomized trial
19). There are other elements of this story that we mustcknowledge, including conflicts of interest (20) and aggres-
ive direct-to-consumer advertising, advertising that often
xploits people’s fears (21). We in the biomedical research
ommunity have a moral responsibility to remember our
any past failures (19) and to insist upon appropriate levels
f skepticism, especially for interventions that are likely to
ffect large swaths of the population.
Shah (18) is absolutely right. There should be no double
tandard. Biomedical researchers have performed large-scale
andomized trials on a variety of screening tests, and
creening tests for coronary artery disease should be subject
o the same level of rigor. Shah (18) is correct when he
oints out the Framingham Risk Score has not been tested
n a rigorous way, and indeed prominent authorities have
ppropriately questioned the value of widespread global risk
coring in the absence of proper evidence (22). It is not at all
lear that the risk stratification paradigm is the best way to
educe substantially the burden of clinically active coronary
rtery disease in our population.
Thanks to the diligent work of many talented cardiovas-
ular researchers, we now have a myriad of potentially valid
pproaches to assess risk and reduce population coronary
rtery disease burden. These include global risk scoring,
oronary calcium or carotid screening, measurement of
iomarkers such as high-sensitivity C-reactive protein, and
idespread use of statins or polypills. We should not forget
bout population-based strategies, such as smoking bans,
nd legal prohibition of toxic dietary substances such as
rans-fats and highly salted foods. Our next step is to have
he humility to admit that we do not know which approach
r combination of approaches is best, but that, in the public
nterest, we will join forces to design and implement the
efinitive large-scale randomized trials that our patients and
he public should rightly demand.
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